Sign Out
Passive immunisation against hepatitis A infection
Adult: As 15-18% protein inj: Postexposure prophylaxis: 0.1 mL/kg given as soon as possible within 14 days of exposure. Preexposure prophylaxis in patients travelling to areas with endemic hepatitis A: <1 month length of stay: 0.1 mL/kg; 1-2 months length of stay: 0.2 mL/kg; >2 months length of stay: 0.2 mL/kg every 2 months. Doses are given via deep IM inj.
Intramuscular
Prevent or modify measles attack in immunocompromised patients
Adult: Postexposure prophylaxis in susceptible patients (unvaccinated individuals who have not previously had measles): As 15-18% protein inj: 0.25 mL/kg given via deep IM inj within 6 days after exposure.
Child: Postexposure prophylaxis in immunocompromised patients: As 15-18% protein inj: 0.5 mL/kg (Max: 15 mL) given via deep IM inj immediately after exposure.
Child: Postexposure prophylaxis in immunocompromised patients: As 15-18% protein inj: 0.5 mL/kg (Max: 15 mL) given via deep IM inj immediately after exposure.
Intramuscular
Passive immunisation against varicella infections
Adult: As an alternative agent to modify varicella in immunosuppressed patients only if varicella-zoster immune globulin is not available: As 15-18% protein inj: 0.6-1.2 mL/kg as a single dose via deep IM inj given promptly or within 72 hours of exposure. Recommendations may vary among countries (refer to specific product or local guidelines).
Intravenous
Multifocal motor neuropathy
Adult: Initially, 2,000 mg/kg given in divided doses over 2-5 consecutive days (e.g. 400 mg/kg once daily for 5 days). Maintenance: 1,000 mg/kg every 2-4 weeks or 2,000 mg/kg every 4-8 weeks. Doses are given via IV infusion (initial rate may be gradually increased based on tolerability). Dosage and frequency are individualised and adjusted according to the clinical response. Evaluate the therapy effect after each cycle. Dosage and treatment recommendations may vary among individual products and between countries (refer to specific product or local guidelines).
Intravenous
Chronic inflammatory demyelinating polyneuropathy
Adult: Initially, 2,000 mg/kg given in divided doses over 2-5 consecutive days (e.g. 400 mg/kg once daily for 5 days). Maintenance: 1,000 mg/kg as a single infusion over 1 day or 1,000 mg/kg divided into 2 doses over 2 consecutive days given every 3 weeks. Doses are given via IV infusion (initial rate may be gradually increased based on tolerability). Dosage and frequency are individualised and adjusted according to the clinical response. Continue for 2-3 months then assess response to therapy. Dosage and treatment recommendations may vary among individual products and between countries (refer to specific product or local guidelines).
Intravenous
Kawasaki disease
Adult: In combination with aspirin: 2,000 mg/kg as a single dose. Alternatively, 1,600-2,000 mg/kg in divided doses over 2-5 days may be given. Doses are given via IV infusion (initial rate may be gradually increased based on tolerability). Dosage and treatment recommendations may vary among individual products and between countries (refer to specific product or local guidelines).
Intravenous
Guillain-Barre syndrome
Adult: 400 mg/kg daily for 5 consecutive days. Treatment may be repeated if relapse occurs. Doses are given via IV infusion (initial rate may be gradually increased based on tolerability). Dosage and treatment recommendations may vary among individual products and between countries (refer to specific product or local guidelines).
Intravenous
Primary immunodeficiency
Adult: As replacement therapy in primary immunodeficiency diseases, including congenital agammaglobulinaemia, common variable deficiency, Wiskott-Aldrich syndrome, and severe combined immunodeficiencies: Initially, 400-800 mg/kg, followed by 200 mg/kg every 3-4 weeks. Maintenance: 200-800 mg/kg per month. Doses are given via IV infusion (initial rate may be gradually increased based on tolerability). Consistent IgG trough levels are reached after 3-6 months of therapy. Doses must be individualised and adjusted according to IgG trough concentrations, clinical response, or as necessary to achieve optimal protection against infections. Dosage, frequency and duration recommendations, instructions for administration, and switching between products or routes of administration may vary among individual products and between countries (refer to specific product or local guidelines).
Intravenous
Idiopathic thrombocytopenic purpura
Adult: In patients at high risk of bleeding or given prior to surgery to correct platelet count: 800-1,000 mg/kg given on day 1, may be repeated once within 3 days. Alternatively, 400 mg/kg daily for 2-5 days may be given. Treatment may be repeated if relapse occurs. Doses are given via IV infusion (initial rate may be gradually increased based on tolerability). Dosage, frequency and duration recommendations may vary among individual products and between countries (refer to specific product or local guidelines).
Intravenous
Secondary immunodeficiency
Adult: As replacement therapy in patients who suffer from severe or recurrent infections, ineffective antimicrobial treatment, and either proven specific antibody failure or <4 g/L serum IgG levels: 200-400 mg/kg every 3-4 weeks. Doses are given via IV infusion (initial rate may be gradually increased based on tolerability). Doses must be individualised and adjusted according to IgG trough concentrations, individual clinical response, or as necessary to achieve optimal protection against infections. Dosage, frequency and duration recommendations may vary among individual products and between countries (refer to specific product or local guidelines).
Subcutaneous
Chronic inflammatory demyelinating polyneuropathy
Adult: As maintenance therapy after stabilisation with IVIg treatment: Initiate therapy 1 week after the last IVIg infusion. Recommended dose: 200-400 mg/kg weekly given in 1 or 2 sessions over 1 or 2 consecutive days. The starting dose may be a 1:1 conversion of the previous IVIg dose (calculated as a weekly dose). Adjust the dose based on clinical response. If symptoms worsen on 200 mg/kg weekly dose, dose may be increased to 400 mg/kg weekly. If symptoms worsen with 400 mg/kg weekly dose, consider re-initiating IVIg treatment and discontinuing the SC dose. Doses may be given via SC infusion using a device/pump or by manual push using a syringe (refer to detailed product guidelines for specific administration instructions). Infusion rate depends on the patient's needs. Dosage, frequency and duration recommendations, instructions for administration, and switching between products or routes of administration may vary among individual products and between countries (refer to specific product or local guidelines).
Subcutaneous
Primary immunodeficiency
Adult: As replacement therapy in primary immunodeficiency diseases, including congenital agammaglobulinaemia, common variable deficiency, Wiskott-Aldrich syndrome, and severe combined immunodeficiencies: 200-500 mg/kg as a loading dose (may be divided over several days), followed by a maintenance dose administered at repeated intervals to reach a cumulative monthly dose of 400-800 mg/kg. Doses may be given via SC infusion using a device/pump or by manual push using a syringe (refer to detailed product guidelines for specific administration instructions). Infusion rate depends on the patient's needs. Dosage and dosing intervals must be individualised and adjusted according to IgG trough concentrations and clinical response (e.g. infection rate). Dosage, frequency and duration recommendations, instructions for administration, and switching between products or routes of administration may vary among individual products and between countries (refer to specific product or local guidelines).
